Drug: |
||||
---|---|---|---|---|
Trial Name: |
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Completed |
|||
Phase: |
1 |
Start Date 01/01/2004 |
Age of Trial (yrs) 20.9 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor |
|||
Strategy: |
Block KIT |
|||
Trial Type: |
GIST not specified. GIST patients known to be enrolled. |
|||
Other Protocol IDs: |
||||
Sponsor: |
AB Science |
|||
Patient Contact: |
||||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
Trial Links |
Trial Results |
Name |
Address |
City |
State |
Zip |
Country |
Villejuif |
Val de Narne |
94805 |
France |
||
28 rue Laennec |
Lyon |
Rhone |
69373 |
France |
|
229 Cours Argonne |
Bordeaux |
Gironde |
33076 |
France |